Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy

This publication has 30 references indexed in Scilit:

• REGN727/SAR236553, A FULLY HUMAN PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) MONOCLONAL ANTIBODY: EFFECTS ON SAFETY AND LIPID AND LIPOPROTEIN PROFILES WHEN ADMINISTERED SUBCUTANEOUSLY
  Journal of the American College of Cardiology, 2011
• Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With Rosuvastatin
  Journal of the American College of Cardiology, 2011
• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
  The Lancet, 2010
• Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis
  Published by Elsevier ,2008
• Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart Disease
  New England Journal of Medicine, 2006
• Assessment of Reaching Goal in Patients with Combined Hyperlipidemia: Low-Density Lipoprotein Cholesterol, Non–High-Density Lipoprotein Cholesterol, or Apolipoprotein B
  The American Journal of Cardiology, 2005
• Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin Therapy
  Journal of the American College of Cardiology, 2005
• Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey and Implications for Treatment Under the Recent NCEP Writing Group Recommendations
  The American Journal of Cardiology, 2005
• Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
  Nature Genetics, 2003
• The College of American Pathologists laboratory accreditation program
  Accreditation and Quality Assurance, 2002